Evidence mapPaperPMID 41828665Full record

ReviewInternational journal of molecular sciences2026

The Role of Exosomes in the Regulation of Molecular Mechanisms Underlying Treatment Resistance-Linking Cellular Crosstalk to Clinical Implications in Depression.

Kinga Dyndał, Patrycja Pańczyszyn-Trzewik, Bernadetta Jakubowska, Magdalena Sowa-Kućma

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kinga DyndałStudent Scientific Club "NEURON", Faculty of Medicine, Collegium Medicum, University of Rzeszów, Al. Tadeusza Rejtana 16C, 35-959 Rzeszów, Poland.ORCID 0009-0008-0753-4837
Patrycja Pańczyszyn-TrzewikDepartment of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzeszów, Al. Tadeusza Rejtana 16C, 35-959 Rzeszów, Poland.ORCID 0000-0001-8760-7494
Bernadetta JakubowskaStudent Scientific Club "NEURON", Faculty of Medicine, Collegium Medicum, University of Rzeszów, Al. Tadeusza Rejtana 16C, 35-959 Rzeszów, Poland.
Magdalena Sowa-KućmaDepartment of Human Physiology, Faculty of Medicine, Collegium Medicum, University of Rzeszów, Al. Tadeusza Rejtana 16C, 35-959 Rzeszów, Poland.ORCID 0000-0001-5956-7229

Funding

Minister of Science in Poland SKN/SP/603081/2024
6 · The paper itself

Abstract

Depressive disorders (DDs), especially treatment-resistant depression (TRD), pose a significant challenge worldwide, largely because their underlying biological mechanisms are complicated and treatments often fall short. There is growing evidence pointing to factors like disrupted neuroplasticity, neuroinflammation, irregularities in the hypothalamic-pituitary-adrenal (HPA) axis, and glutamatergic system imbalances as contributors to the onset and persistence of depressive symptoms. Exosomes (small extracellular vesicles involved in communication between cells) have recently gained attention for their potential role in connecting peripheral and central nervous system (CNS) changes. They carry proteins, lipids, and nucleic acids and are even capable of crossing the blood-brain barrier. Because of this, exosomes might provide a window into molecular changes in the brain and serve as accessible biomarkers of disease status and treatment response. Recent research points out that the contents of exosomes, especially microRNAs (miRNAs) and neurotrophic factors like brain-derived neurotrophic factor (BDNF), might play a part in disrupting synaptic plasticity and could be linked to resistance to antidepressants. At the same time, there is growing interest in using engineered exosomes as targeted drug carriers aimed at the CNS. That said, there are still quite a few hurdles to overcome. Methods vary widely between studies, protocols for isolating exosomes are not sufficiently standardized, safety data are limited, and we do not fully understand how drugs and exosomes interact or how they behave pharmacokinetically. This review brings together current findings regarding exosomes in DDs (with particular emphasis on TRD), highlights their promise for diagnosis and treatment, and sets out some of the main questions that need to be answered before clinical application becomes feasible.

Indexed as

DepressionDepressive Disorder, Treatment-ResistantExosomesAnimalsAntidepressive AgentsBrain-Derived Neurotrophic FactorHumansMicroRNAsNeuronal PlasticityAntidepressive AgentsBrain-Derived Neurotrophic FactorMicroRNAsdepressive disordersexosomesmulti-omicsneuroinflammationneuroplasticityoxidative stressTRD

Identifiers

PMID41828665
PMCPMC12986393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.